Press Releases

Press Releases

  1. BTG plc: Appointment of Non-executive Director

  2. BTG plc: US FDA approves expanded ZYTIGA® indication for treatment of metastatic castration-resistant prostate cancer

  3. BTG plc: Janssen announces that ZYTIGA® has received a positive opinion in the EU for treating chemo-naïve mCRPC patients

  4. Full data from pivotal Phase III trials of Varisolve® PEM presented at the 26th Annual Congress of the American College of Phlebology

  5. BTG plc: Interim Results

  6. BTG plc: Close Period Update

  7. BTG to present at the UBS Global Life Sciences Conference

  8. BTG to present at the Bank of America Merrill Lynch Global Healthcare Conference

  9. CMS grants new prospective reimbursement for Voraxaze®

  10. BTG Announces Data from Phase IIb Study of AZD9773

  11. BTG plc: Interim Management Statement

  12. BTG plc: Applications submitted to FDA and EMA for approval of Lemtrada™ (alemtuzumab) for Multiple Sclerosis

  13. BTG announces data presentation on Voraxaze® (glucarpidase) at the American Society of Clinical Oncology Annual Meeting

  14. BTG to present at the Jefferies Global Healthcare Conference

  15. BTG plc: Final Results

  16. Voraxaze® (glucarpidase) Launched in the US

  17. BTG Announces Positive Results from Second US Pivotal Phase III Trial of Varisolve®

  18. BTG plc: Close Period Update

  19. DigiFab® 40 mg/vial digoxin immune Fab

  20. BTG plc: ZYTIGA® (abiraterone acetate) second Phase III trial unblinded

  21. BTG to present at the Citi Global Health Care Conference

  22. BTG plc: Directorate Change Amendment

  23. BTG Announces Positive Data from First US Phase III Trial of Varisolve®

  24. BTG plc: Interim Management Statement

  25. BTG plc: Voraxaze® (glucarpidase) receives US regulatory approval

  26. BTG to present at the 30th Annual J.P. Morgan Healthcare Conference